Brief: Mustang Bio Announces Positive Opinion From The European Medicines Agency On Orphan Drug Designation For Its Lentiviral Gene Therapy For The Treatment Of X-Linked Severe Combined Immunodeficiency
24/11/2020 13:19
Nov 24 (Reuters) - Mustang Bio Inc MBIO.O :
* MUSTANG BIO ANNOUNCES POSITIVE OPINION FROM THE EUROPEAN
MEDICINES AGENCY ON ORPHAN DRUG DESIGNATION FOR ITS LENTIVIRAL
GENE THERAPY FOR THE TREATMENT OF X-LINKED SEVERE COMBINED
IMMUNODEFICIENCY (“XSCID”)
* MUSTANG BIO INC - TARGETING TOPLINE DATA FROM PHASE 2
TRIAL IN
SECOND HALF OF 2022
Source text for Eikon: ID:nGNX50MKvb
Further company coverage: MBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mustang Bio
See all newsAdvisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
U.S. STOCKS ON THE MOVE-Dow, Phibro, Mustang Bio
Mustang soars on FDA's orphan drug tag for brain cancer therapy
Mustang Bio Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Mustang Bio Inc - Enters Sale And Surrender Agreement With Abbvie